Description
CL2A-SN-38 is a cleavable linker-based antibody-drug conjugate (ADC) containing the topoisomerase I inhibitor SN-38 (Item No. 15632) and a maleimidocaproyl linker.1 CL2A-SN-38 has been linked to tumor-selective humanized antibodies, such as anti-Trop-2 (hRS7), to target SN-38 to tumor sites. CL2A-SN-38 linked to hRS7 is cytotoxic to Calu-3, COLO 205, Capan-1, PC3, SK-MES-1, and BxPC-3 cancer cells (IC50s =1.95-23.14 nM). CL2A-SN-38 linked to hRS7 reduces tumor growth in BxPC-3 pancreatic and SK-MES-1 lung cancer mouse xenograft models.WARNING This product is not for human or veterinary use.
References
[1] THOMAS M CARDILLO. Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeys.[J]. Clinical Cancer Research, 2011, 17 10: 3157-3169. DOI:
10.1158/1078-0432.ccr-10-2939
